Stock A009290 KWANG DONG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Kwang Dong Pharmaceutical Co., Ltd.

Equities

A009290

KR7009290008

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 04/06/2024 BST 		5-day change 1st Jan Change
6,580 KRW -0.15% Intraday chart for Kwang Dong Pharmaceutical Co., Ltd. -1.20% -11.44%
05-16 Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-18 Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Distribute Eye Drop in Korea
MT
Bioleaders Corporation announced that it has received KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.
CI
Bioleaders Corporation announced that it expects to receive KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.
CI
Kwang Dong Pharmaceutical Co., Ltd. agreed to acquire a 58.73% stake in BL Healthcare Corp. from BL Healthcare Corp. for KRW 30 billion
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Tranche Update on Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on April 11, 2023.
CI
Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback announced on April 11, 2023, has closed with 1,000,000 shares, representing 2.43% for KRW 6,228.66 million.
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Kwang Dong Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,000,000 shares.
CI
Kwang Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Commercialize Myopia Drug in South Korea
MT
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
Oxford Cancer Biomarkers Ltd announced that it has received funding from Kwang Dong Pharmaceutical Co., Ltd.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A009290 Stock
  4. News Kwang Dong Pharmaceutical Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW